TORNTPHARM
Torrent Pharmaceuticals Limited (TORNTPHARM) Stock Analysis
Torrent Pharmaceuticals Limited is a major Indian pharma company with strong brands in cardiovascular, CNS, and gastro therapies. It markets generics and branded medicines in India and operates manufacturing with international subsidiaries. The company is part of the Torrent Group with a focus on chronic therapies. It is listed on the NSE and BSE.
Healthcare › Drug Manufacturers - Specialty & Generic
₹4,656.90
-2.32% 1W | +33.50% 52W
Market Cap
177.1k CR
P/E Ratio
74.4
52W High
₹5250
52W Low
₹3480.6
Div. Yield
0.82%
Beta
0.1
50 DMA
₹4919.2
200 DMA
₹4482
Profit Margin
13.9%
Inst. Own.
19.5%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,591 | 2,660 | 2,732 | 2,745 | 2,859 | 2,889 | 2,809 | 2,959 | 3,178 | 3,302 | 3,303 | 4,197 | 4,921 |
| Expenses | 1,800 | 1,835 | 1,863 | 1,862 | 1,955 | 1,950 | 1,895 | 1,995 | 2,146 | 2,219 | 2,215 | 2,841 | 3,257 |
| Operating Profit | 791 | 825 | 869 | 883 | 904 | 939 | 914 | 964 | 1,032 | 1,083 | 1,088 | 1,356 | 1,664 |
| OPM % | 31% | 31% | 32% | 32% | 32% | 32% | 33% | 33% | 32% | 33% | 33% | 32% | 34% |
| Other Income | 34 | 26 | 55 | 31 | 24 | -16 | 33 | -42 | -37 | -40 | -23 | -83 | -33 |
| Interest | 103 | 91 | 80 | 80 | 75 | 64 | 57 | 56 | 56 | 48 | 45 | 236 | 305 |
| Depreciation | 191 | 201 | 213 | 203 | 197 | 198 | 199 | 201 | 201 | 204 | 206 | 508 | 593 |
| Profit before tax | 531 | 559 | 631 | 631 | 656 | 661 | 691 | 665 | 738 | 791 | 814 | 529 | 733 |
| Tax % | 29% | 31% | 30% | 29% | 30% | 31% | 27% | 25% | 26% | 25% | 22% | 31% | 23% |
| Net Profit | 378 | 386 | 443 | 449 | 457 | 453 | 503 | 498 | 548 | 591 | 635 | 364 | 566 |
| EPS in Rs | 11.17 | 11.41 | 13.09 | 13.27 | 13.50 | 13.38 | 14.86 | 14.71 | 16.19 | 17.46 | 18.76 | 10.76 | 16.72 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,636 | 6,687 | 5,816 | 5,950 | 7,673 | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 11,516 | 13,980 | 15,723 |
| Expenses | 3,616 | 3,954 | 4,438 | 4,601 | 5,690 | 5,769 | 5,524 | 6,077 | 6,778 | 7,360 | 7,795 | 9,421 | 10,532 |
| Operating Profit | 1,020 | 2,733 | 1,377 | 1,349 | 1,983 | 2,170 | 2,480 | 2,431 | 2,842 | 3,368 | 3,721 | 4,558 | 5,191 |
| OPM % | 22% | 41% | 24% | 23% | 26% | 27% | 31% | 29% | 30% | 31% | 32% | 33% | 33% |
| Other Income | 286 | 32 | 223 | 299 | -300 | 121 | 57 | -288 | 45 | 146 | -1 | -182 | -179 |
| Interest | 175 | 184 | 206 | 308 | 504 | 451 | 353 | 255 | 333 | 354 | 252 | 385 | 634 |
| Depreciation | 191 | 238 | 307 | 409 | 618 | 654 | 658 | 662 | 707 | 808 | 795 | 1,119 | 1,511 |
| Profit before tax | 940 | 2,343 | 1,088 | 931 | 562 | 1,187 | 1,526 | 1,226 | 1,847 | 2,352 | 2,673 | 2,872 | 2,867 |
| Tax % | 20% | 26% | 14% | 27% | 22% | 14% | 18% | 37% | 33% | 30% | 28% | 26% | |
| Net Profit | 751 | 1,733 | 934 | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,911 | 2,138 | 2,156 |
| EPS in Rs | 22.19 | 51.22 | 27.59 | 20.04 | 12.89 | 30.28 | 36.99 | 22.97 | 36.79 | 48.94 | 56.47 | 63.92 | 63.70 |
| Dividend Payout % | 25% | 34% | 25% | 35% | 66% | 53% | 47% | 105% | 60% | 57% | 57% | 59% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 13.0% | 12.0% | 8.0% |
| Profit CAGR | 22.0% | 12.0% | 2.0% |
Shareholding Pattern
Promoters68.31%
FIIs15.92%
DIIs9.17%
Public6.47%
Promoters68.31%
FIIs16.13%
DIIs9.05%
Public6.41%
Promoters68.31%
FIIs16.18%
DIIs8.96%
Public6.55%
Promoters68.31%
FIIs15.44%
DIIs9.73%
Public6.42%
Promoters60.78%
FIIs17.97%
DIIs12.77%
Public8.39%
Promoters71.25%
FIIs12.04%
DIIs8.89%
Public7.71%
Promoters71.25%
FIIs14.14%
DIIs7.15%
Public7.34%
Promoters68.31%
FIIs16.31%
DIIs8.25%
Public7.02%
Promoters68.31%
FIIs16.18%
DIIs8.96%
Public6.55%
Promoters60.78%
FIIs17.97%
DIIs12.77%
Public8.39%
TORNTPHARM
Holdings Analysis
Key strengths & risk signals
72
Overall
77
Fundamental
68
Technical
Risks (3)
OVERVALUED! PEG of 3.68 means expensive relative to growth rate.
RECOVERY MODE! Current price (4656.9) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 2.3% (1 week), 5.5% (1 month), 5.0% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (4919.2) is above 200-day average (4482.0) - positive signal.
GOOD YEAR! Stock gained 33.5% in the last year.
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
Fundamental & Technical Analysis
72Overall
77Fundamental
68Technical
Fundamental Breakdown
Growth Quality
26/30
Revenue CAGR: 13.3% (GOOD, 11/15). Profit CAGR: 20.2% (EXCELLENT, 15/15).
Profit Margin
5/10
DECENT EFFICIENCY! 13.9% profit margin - acceptable profitability.
PEG Valuation
3/10
OVERVALUED! PEG of 3.68 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.82% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 7.59% public ownership - strong promoter/institutional control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (4919.2) is above 200-day average (4482.0) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (4656.9) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
GOOD YEAR! Stock gained 33.5% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 14 up days, 14 down days. Avg volume on up days: 361,939 vs down days: 336,162. Ratio: 1.08x
RSI
4/5
APPROACHING OVERSOLD! RSI at 37.0 - watch for reversal.
52W Range
4/5
UPPER HALF! Trading at 66.5% of 52W range - positive territory.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 2.3% (1 week), 5.5% (1 month), 5.0% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
TORNTPHARM
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q3FY262026-02-20 | Concall PDF | |
| Q2FY262025-11-13 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TORNTPHARM | ₹4,656.90 | 74.4 | 13.9% | 13.3% | 20.2% | +33.5% | 72 | BREAKDOWN | +3.3% | +45.5% | +54.6% | +17.1% |
| ZYDUSLIFE | ₹1,117.50 | 24.9 | 15.8% | 16.5% | 37.0% | +15.9% | 75 | APPROACHING SUPPORT | -35.9% | -26.1% | +20.6% | +4.9% |
| LAURUSLABS | ₹2,036.60 | 100.7 | 15.0% | 3.8% | 4.0% | +127.9% | 55 | CONSOLIDATING UP | +125.5% | +31.7% | +29.1% | +11.9% |
| DIVISLAB | ₹9,340.00 | 84.7 | 26.0% | 11.0% | 12.1% | +56.4% | 75 | BREAKDOWN | +65.5% | +20.1% | +27.8% | +8.8% |
| CIPLA | ₹1,301.00 | 31.2 | 12.0% | 7.2% | 11.5% | -16.3% | 60 | APPROACHING SUPPORT | -39.2% | +42.3% | +3.5% | +9.5% |
| DRREDDY | ₹1,197.00 | 30.1 | 10.0% | 11.0% | -1.7% | -3.4% | 63 | BREAKOUT | -68.7% | +100.8% | -5.6% | +7.4% |
| MANKIND | ₹2,368.50 | 47.9 | 13.9% | 17.7% | 14.3% | -3.2% | 70 | APPROACHING SUPPORT | +29.6% | +2.5% | +12.9% | +17.1% |
| AUROPHARMA | ₹1,693.00 | 26.5 | 10.6% | 10.7% | 22.1% | +45.5% | 81 | APPROACHING RESISTANCE | +25.2% | +12.1% | +16.9% | +4.0% |
Data from TradeAlone · Updated daily
TORNTPHARM News
Torrent Pharmaceuticals Limited (TORNTPHARM) breaks out, gains 5% intraday2026-07-31Torrent Pharmaceuticals Limited (TORNTPHARM) clears resistance, moves up 5% intraday2026-07-20Torrent Pharmaceuticals Limited (TORNTPHARM) cools off after resistance breakout, down 5%2026-07-17Torrent Pharmaceuticals Limited (torntpharm) Implements Voluntary Recall for Semalix Injection Disposable Pens2026-07-09Torrent Pharmaceuticals Limited (torntpharm) Q4 FY26: Revenue Surges 43% to ₹2,215 Cr2026-05-22
